Industry: Pharmaceuticals, Biotechnology
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore, RegeneRx is developing TB4 as the cornerstone of its therapeutic platform. The technology platform has many potential applications in both the pharmaceutical and consumer products sectors. RegeneRx holds nearly 60 world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, septic shock and several consumer product ( www.regenerx.com )
RegeneRx Biopharmaceuticals , Inc.
3 Bethesda Metro Center Suite 630
Bethesda, Maryland 20814
USA
Tel: (301) 280-1992
Fax: (301) 280-1996